Interestingly, the primary reason physicians in this study said they prescribed GLP-1 RAs, SGLT2 inhibitors, and pioglitazone was to assist with weight loss; improvement or reversal of steatosis was the second most common reason. The gene discussed is GLP1R; the disease is steatosis.